Table 4 Drug specificity of the top 500 genes identified using ProGENI and Pearson correlation scheme using the LCL dataset
From: Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance
Treatment | Rank by ProGENI (p value) | Rank by PCC (p value) |
|---|---|---|
6MP | 3 (0.13) | 1 (0.04) |
6TG | 23 (0.96) | 5 (0.21) |
Arac | 9 (0.38) | 4 (017) |
Arsenic | 12 (0.5) | 12 (0.5) |
Carboplatin | 5 (0.21) | 2 (0.08) |
Cddp | 8 (0.33) | 3 (0.13) |
Cladribine | 2 (0.08) | 3 (0.13) |
Docetaxel | 1 (0.04) | 1 (0.04) |
Doxorubicin | 2 (0.08) | 2 (0.08) |
Epirubicin | 2 (0.08) | 2 (0.08) |
Everolimus | 12 (0.5) | 2 (0.08) |
Fludarabine | 11 (0.46) | 8 (0.33) |
Gemcitabine | 2 (0.08) | 1 (0.04) |
Hypoxia | 2 (0.08) | 1 (0.04) |
Metformin | 3 (013) | 7 (0.29) |
MPA | 1 (0.04) | 1 (0.04) |
MTX | 13 (0.54) | 18 (0.75) |
NAPQI | 11 (0.46) | 1 (0.04) |
Oxaliplatin | 1 (0.04) | 1 (0.04) |
Paclitaxel | 1 (0.04) | 1 (0.04) |
Radiation | 24 (1) | 24 (1) |
Rapamycin | 2 (0.08) | 2 (0.08) |
TCN | 11 (0.46) | 23 (0.96) |
TMZ | 15 (0.63) | 16 (0.67) |